Should myocardial infarction type 2 be regarded as two separate entities?

European Heart Journal

Volumn 40, Issue 33, 2019, Pages 2810-2812

  Thygesen, Kristian ^a   Jaffe, Allan S ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE 9; TROPONIN; MONOCLONAL ANTIBODY;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; HEART INFARCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; TYPE 1 MYOCARDIAL INFARCTION; TYPE 2 MYOCARDIAL INFARCTION; ANTERIOR MYOCARDIAL INFARCTION; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANTERIOR WALL MYOCARDIAL INFARCTION; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, TYPE 2; HUMANS; MYOCARDIAL INFARCTION;

EID: 85072058900     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehz451     Document Type: Review

References (16)

1. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525–2538.
2. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551–2567.
3. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, BAX JJ, Morrow DA, White HD, the Executive Group on behalf of the Joint ESC/ACC/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019;40:237–269.
4. Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher D, Sabti Z, Puelacher C, Rubini Giménez M, Kozhuharov N, Strebel I, Sazgary L, Schneider D, Jann J, du Fay de Lavallaz J, Miró Ò, Martin-Sanchez FJ, Morawiec B, Kawecki D, Muzyk P, Keller DI, Geigy N, Osswald S, Reichlin T, Mueller C; APACE Investigators. Effect of definition on incidence and prognosis of type 2 myocardial infarction. J Am Coll Cardiol 2017;70:1558–1568.
5. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B, Total-AMI study group. Impact on long-term mortality of presence of obstructive coronary artery disease and classification of myocardial infarction. Am J Med 2016;129: 398–406.
6. Chapman AR, Shah ASV, Lee KK, Anand A, Francis O, Adamson P, McAllister DA, Strachan FE, Newby DE, Mills NL. Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury. Circulation 2018;137: 1236–1245.
7. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018;39:119–177.
8. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, da Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016; 37:267–315.
9. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. Graham I, De Backer G. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999–3058.
10. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome N Engl J Med 2018;379:2097–2107.
11. White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG; for the ODYSSEY OUTCOMES Investigators. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. Eur Heart J 2019;40:2801–2809.
12. Gard A, Lindahl B, Batra G, Hadziosmanovic N, Hjort M, Szummer KE, Baron T. Interphysician agreement on subclassification of myocardial infarction. Heart 2018;104:1284–1291.
13. Sandoval Y, Jaffe AS. Type 2 myocardial infarction. J Am Cardiol Coll 2019;73: 1846–1860.
14. Olesen KKW, Barkholt TØ and Meang M. Myocardial infarction with non-obstructive thrombus validated by optical coherence tomography. Scand Card J 2017; 51:61–68.
15. Maehara A, Mintz GS, Bui AB, Walter OR, Castagna MT, Canos D, Pichard AD, Satler LF, Waksman R, Suddath WO, Laird JR Jr, Kent KM, Weissman NJ. Morphologic and angiographic features of coronary plaque rupture detected by intravascular ultrasound. J Am Coll Cardiol 2002;40:904–910.
16. Lambrakis K, French JK, Scott IA,, Briffa T, Brieger D, Farkouh ME, White H, Chuang AM, Tiver K, Quinn S, Kaambwa B, Horsfall M, Morton E, Chew DP. The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): a randomized trial design. Am Heart J 2019;208: 11–20.